Fresh licensing and collaboration announcements are reinforcing degrader momentum at Big Pharma. Gilead’s decision to exclusively license Kymera’s KT-200 CDK2 molecular glue degrader adds another oral degradation asset, while Roche’s new DAC collaboration with C4 Therapeutics targets oncology space with antibody-guided degradation payloads. These deals share a common operational theme: integrating degradation with delivery and tumor targeting to improve therapeutic index. They also show how Big Pharma is using structured milestone-heavy arrangements to manage risk while still gaining access to differentiated modality IP. Together, the announcements highlight that degradation is moving from early discovery into pipeline construction, where partners and licensors are expected to drive IND-enabling development timelines and preclinical differentiation. For industry observers, the combined activity points to the near-term focus of modality teams: finding the right targets, maintaining selectivity, and demonstrating tolerability under the delivery constraints typical of oncology therapeutics.